Brolucizumab for treating diabetic macular oedema

2.1 Brolucizumab (Beovu, Novartis) is indicated 'for the treatment of visual impairment due to diabetic macular oedema'.

2.2 The dosage schedule is available in the summary of product characteristics for brolucizumab.

2.3 Brolucizumab costs £816 for 1 vial of 120 mg per 1 ml solution for injection (excluding VAT; BNF online, accessed July 2022).

2.4 The company has a commercial arrangement. This makes brolucizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.